drugset
drugset / Trial / NCT05941156

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

NCT05941156 ↗

Phase 2 Unknown 20 enrolled The Affiliated Hospital of Xuzhou Medical University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of anti-CD56-CAR T in the treatment of relapsed refractory NK/T cell lymphoma /NK cell leukemia

Timeline

Start
2023-05-01
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti CD56-CAR T Cell therapy — Other

Indications

T-cell and NK-cell neoplasm extranodal nasal NK/T cell lymphoma